Serum uric acid-lowering therapies: Where are we heading in management of hyperuricemia and the potential role of uricase

Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase. However, several new therapies have been developed. Recombinant urate oxidase has been useful in the treatment of tumor lysis hyperuricemia, and pegylated urate oxidase shows promise in patients with hyperuricemia and gout. Febuxostat and Y-700 are new oral xanthine oxidase inhibitors that are in human clinical trials. Tailoring of antilipid therapy in selected hyperuricemic and hyperlipidemic patients with fenofibrate may be of benefit in lowering blood cholesterol and uric acid levels. Similarly, treatment of selected hyperuricemic patients who also are hypertensive with losartan or amlodipine may be beneficial in lowering blood pressure and hyperuricemia. Despite these advances, new treatments for hyperuricemia are needed.

[1]  M. Holdsworth,et al.  Role of i.v. allopurinol and rasburicase in tumor lysis syndrome. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[2]  J. Beilby,et al.  Sample preparation in patients receiving uric acid oxidase (rasburicase) therapy. , 2003, Clinical chemistry.

[3]  Y. Moriwaki,et al.  Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[4]  T. Johns,et al.  Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. , 1999, Journal of ethnopharmacology.

[5]  S. Ball,et al.  Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. , 2003, Rheumatology.

[6]  A. Franco,et al.  Acute Uric Acid Nephropathy by Overdosage of Benziodarone in a Renal Transplant Recipient , 2002, Nephron.

[7]  N. Takahata,et al.  Loss of urate oxidase activity in hominoids and its evolutionary implications. , 2002, Molecular biology and evolution.

[8]  Kao‐Ping Chang,et al.  The Soft-Tissue Shaving Procedure for Deformity Management of Chronic Tophaceous Gout , 2003, Annals of plastic surgery.

[9]  S. Gabriel,et al.  Epidemiology of gout: is the incidence rising? , 2002, The Journal of rheumatology.

[10]  H. Van den Berg,et al.  Renal tubular damage in rasburicase: risks of alkalinisation. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Kong,et al.  A literature review of the epidemiology and treatment of acute gout. , 2003, Clinical therapeutics.

[12]  C. Pui,et al.  Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies. , 2003, Clinical lymphoma.

[13]  Y. Moriwaki,et al.  Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism , 2003, Annals of the rheumatic diseases.

[14]  H. Schumacher,et al.  Intra-articular corticosteroid preparations: different characteristics and their effect during inflammation induced by monosodium urate crystals in the rat subcutaneous air pouch. , 2003, Rheumatology.

[15]  H. Inoue,et al.  Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[16]  M. Elisaf,et al.  The Effects of the Addition of Micronised Fenofibrate on Uric Acid Metabolism in Patients Receiving Indapamide , 2002, Current medical research and opinion.

[17]  V. Cuervas-Mons,et al.  Chronic renal dysfunction after liver transplantation in adult patients: prevalence, risk factors, and impact on mortality. , 2003, Transplantation proceedings.

[18]  R. Terkeltaub.  Clinical practice. Gout. , 2003, The New England journal of medicine.

[19]  F. Bonneté,et al.  X-ray scattering studies of Aspergillus flavus urate oxidase: towards a better understanding of PEG effects on the crystallization of large proteins. , 2002, Acta crystallographica. Section D, Biological crystallography.

[20]  N. Kamatani,et al.  Trends in the manifestations of gout in Taiwan. , 2003, Rheumatology.

[21]  J. Darmawan,et al.  The effect of control and self-medication of chronic gout in a developing country. Outcome after 10 years. , 2003, The Journal of rheumatology.

[22]  O. Toupance,et al.  Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  O. Yokosuka,et al.  Fulminant hepatic failure associated with benzbromarone treatment: A case report , 2002, Journal of Gastroenterology and Hepatology.

[24]  E. Fernandes,et al.  2-Styrylchromones As Novel Inhibitors of Xanthine Oxidase. A Structure-activity Study , 2002, Journal of enzyme inhibition and medicinal chemistry.

[25]  P. Gow,et al.  A survey of indications, results and complications of surgery for tophaceous gout. , 2002, The New Zealand medical journal.

[26]  Chak-ho Li,et al.  Treatment of Impending Tumor Lysis with Single-Dose Rasburicase , 2003, The Annals of pharmacotherapy.

[27]  R. Hofheinz,et al.  Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome , 2003, Leukemia.

[28]  M. Elisaf,et al.  Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. , 1999, Journal of cardiovascular pharmacology.

[29]  C. Pui,et al.  Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial , 2001, Leukemia.

[30]  M. Relling,et al.  Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Fernandes,et al.  Progress towards the discovery of xanthine oxidase inhibitors. , 2002, Current medicinal chemistry.

[32]  M. Stampfer,et al.  The association between gout and nephrolithiasis in men: The Health Professionals' Follow-Up Study. , 2003, Kidney international.

[33]  R. Prior,et al.  Consumption of cherries lowers plasma urate in healthy women. , 2003, The Journal of nutrition.

[34]  M. Cairo.  Prevention and treatment of hyperuricemia in hematological malignancies. , 2002, Clinical lymphoma.

[35]  N. Colloc'h,et al.  Modification of a reactive cysteine explains differences between rasburicase and Uricozyme®, a natural Aspergillus flavus uricase , 2002, Biotechnology and applied biochemistry.

[36]  F. Tinahones,et al.  The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates. , 2003, Rheumatology.

[37]  F. Ruschitzka,et al.  The management of hyperuricemia and gout in patients with heart failure , 2002, European journal of heart failure.

[38]  R. Terkeltaub,et al.  The case for uricase in gout , 2003, Current Rheumatology Reports.

[39]  G. McCowage,et al.  Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer , 2003, Cancer.

[40]  Y. Park,et al.  Clinical analysis of gouty patients with normouricaemia at diagnosis , 2003, Annals of the rheumatic diseases.

[41]  C. Pui.  Rasburicase: a potent uricolytic agent , 2002, Expert opinion on pharmacotherapy.

[42]  S. Goldman.  Rasburicase: A Viewpoint by Dr Stan Goldman , 2001 .

[43]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[44]  L. A. Bonet.  Predictors of mortality following heart transplantation: Spanish Registry of Heart Transplantation 1984-2001. , 2003, Transplantation Proceedings.

[45]  F. Perez-Ruiz,et al.  Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.

[46]  J. Nolla,et al.  Long-term efficacy of hyperuricaemia treatment in renal transplant patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  M. Feher,et al.  Long-term remission from gout associated with fenofibrate therapy , 2003, Clinical Rheumatology.

[48]  M. Cairo,et al.  A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. , 2001, Blood.

[49]  Qingwen Wang,et al.  Primary gout in Shantou: a clinical and epidemiological study. , 2003, Chinese medical journal.

[50]  P. Hanvivadhanakul,et al.  Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. , 2002, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[51]  R. Tan,et al.  Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout. , 2000, Journal of ethnopharmacology.

[52]  M. Hershfield,et al.  Diabetes Insipidus in Uricase-deficient Mice: a Model for Evaluating Therapy with Poly(ethylene Glycol)-modified Uricase , 2000 .

[53]  B. Coiffier,et al.  Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  C. Liu,et al.  The epidemiology of hyperuricemia in children of Taiwan aborigines. , 2003, The Journal of rheumatology.

[55]  H. Milionis,et al.  Management of Hypertension and Dyslipidaemia in Patients Presenting with Hyperuricaemia: Case Histories , 2000 .

[56]  F. Facchini.  Near-iron deficiency-induced remission of gouty arthritis. , 2003, Rheumatology.

[57]  T. Bardin.  Fenofibrate and losartan , 2003, Annals of the rheumatic diseases.

[58]  E. Pai,et al.  An Extremely Potent Inhibitor of Xanthine Oxidoreductase , 2003, The Journal of Biological Chemistry.

[59]  S. Goldman.  Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies , 2003, Expert review of anticancer therapy.

[60]  Beverley Adams-Huet,et al.  Predictive value of kidney stone composition in the detection of metabolic abnormalities. , 2003, The American journal of medicine.

[61]  J. Bomalaski,et al.  Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. , 2002, The Journal of rheumatology.

[62]  K. Tuttle,et al.  Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? , 2003, Hypertension.

[63]  Yun-Kyoung Song,et al.  Rheumatic pneumonia , 2001, Annals of the rheumatic diseases.

[64]  P. Chong,et al.  Rasburicase for the Treatment and Prevention of Hyperuricemia , 2003, The Annals of pharmacotherapy.

[65]  S. Ito,et al.  A case of exercise-induced acute renal failure in a patient with idiopathic renal hypouricemia developed during antihypertensive therapy with losartan and trichlormethiazide. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[66]  R. Pieters,et al.  Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients , 2003, Supportive Care in Cancer.

[67]  C. Pui.  Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. , 2001, Seminars in hematology.

[68]  C. Pui,et al.  Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002 , 2003, Leukemia.